» Articles » PMID: 23222299

Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer

Overview
Journal Cancer Res
Specialty Oncology
Date 2012 Dec 11
PMID 23222299
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Obese postmenopausal women have increased risk of breast cancers with poorer clinical outcomes than their lean counterparts. However, the mechanisms underlying these associations are poorly understood. Rodent model studies have recently identified a period of vulnerability for mammary cancer promotion, which emerges during weight gain after the loss of ovarian function (surgical ovariectomy; OVX). Thus, a period of transient weight gain may provide a life cycle-specific opportunity to prevent or treat postmenopausal breast cancer. We hypothesized that a combination of impaired metabolic regulation in obese animals prior to OVX plus an OVX-induced positive energy imbalance might cooperate to drive tumor growth and progression. To determine if lean and obese rodents differ in their metabolic response to OVX-induced weight gain, and whether this difference affects later mammary tumor metabolism, we performed a nutrient tracer study during the menopausal window of vulnerability. Lean animals preferentially deposited excess nutrients to mammary and peripheral tissues rather than to the adjacent tumors. Conversely, obese animals deposited excess nutrients into the tumors themselves. Notably, tumors from obese animals also displayed increased expression of the progesterone receptor (PR). Elevated PR expression positively correlated with tumor expression of glycolytic and lipogenic enzymes, glucose uptake, and proliferation markers. Treatment with the antidiabetic drug metformin during ovariectomy-induced weight gain caused tumor regression and downregulation of PR expression in tumors. Clinically, expression array analysis of breast tumors from postmenopausal women revealed that PR expression correlated with a similar pattern of metabolic upregulation, supporting the notion that PR+ tumors have enhanced metabolic capacity after menopause. Our findings have potential explanative power in understanding why obese, postmenopausal women display an increased risk of breast cancer.

Citing Articles

Effects of follicle-stimulating hormone on energy balance and tissue metabolic health after loss of ovarian function.

Libby A, Solt C, Jackman M, Sherk V, Foright R, Johnson G Am J Physiol Endocrinol Metab. 2024; 326(5):E626-E639.

PMID: 38536037 PMC: 11208003. DOI: 10.1152/ajpendo.00400.2023.


Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors.

Harborg S, Cronin-Fenton D, Jensen M, Ahern T, Ewertz M, Borgquist S JAMA Netw Open. 2023; 6(10):e2337780.

PMID: 37831449 PMC: 10576219. DOI: 10.1001/jamanetworkopen.2023.37780.


A retrospective study in tumour characteristics and clinical outcomes of overweight and obese women with breast cancer.

Luis C, Dias J, Firmino-Machado J, Fernandes R, Pereira D, Baylina P Breast Cancer Res Treat. 2022; 198(1):89-101.

PMID: 36576677 PMC: 9883351. DOI: 10.1007/s10549-022-06836-5.


An Exercise-Induced Metabolic Shield in Distant Organs Blocks Cancer Progression and Metastatic Dissemination.

Sheinboim D, Parikh S, Manich P, Markus I, Dahan S, Parikh R Cancer Res. 2022; 82(22):4164-4178.

PMID: 36084256 PMC: 9762351. DOI: 10.1158/0008-5472.CAN-22-0237.


MPA alters metabolic phenotype of endometrial cancer-associated fibroblasts from obese women via IRS2 signaling.

Omar I, Jamil A, Mat Adenan N, Chung I PLoS One. 2022; 17(7):e0270830.

PMID: 35816477 PMC: 9273069. DOI: 10.1371/journal.pone.0270830.


References
1.
Hatzis C, Pusztai L, Valero V, Booser D, Esserman L, Lluch A . A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011; 305(18):1873-81. PMC: 5638042. DOI: 10.1001/jama.2011.593. View

2.
Young C, Anderson S . Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res. 2008; 10(1):202. PMC: 2374962. DOI: 10.1186/bcr1852. View

3.
Thompson H, Adlakha H, Singh M . Effect of carcinogen dose and age at administration on induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis. 1992; 13(9):1535-9. DOI: 10.1093/carcin/13.9.1535. View

4.
Sellers T, Davis J, Cerhan J, Vierkant R, Olson J, Pankratz V . Interaction of waist/hip ratio and family history on the risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women. Am J Epidemiol. 2002; 155(3):225-33. DOI: 10.1093/aje/155.3.225. View

5.
Rogozina O, Bonorden M, Seppanen C, Grande J, Cleary M . Effect of chronic and intermittent calorie restriction on serum adiponectin and leptin and mammary tumorigenesis. Cancer Prev Res (Phila). 2011; 4(4):568-81. PMC: 3071428. DOI: 10.1158/1940-6207.CAPR-10-0140. View